Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Proto-Oncogene Proteins p21\(ras\)"" wg kryterium: Temat


Tytuł :
Acquired Resistance to KRAS Inhibition in Cancer.
Autorzy :
Awad MM; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Liu S; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Rybkin II; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Arbour KC; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Dilly J; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Zhu VW; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Johnson ML; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Heist RS; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Patil T; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Riely GJ; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Jacobson JO; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Yang X; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Persky NS; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Root DE; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Lowder KE; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Feng H; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Zhang SS; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Haigis KM; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Hung YP; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Sholl LM; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Wolpin BM; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Wiese J; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Christiansen J; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Lee J; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Schrock AB; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Lim LP; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Garg K; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Li M; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Engstrom LD; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Waters L; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Lawson JD; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Olson P; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Lito P; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Ou SI; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Christensen JG; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Jänne PA; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Aguirre AJ; From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Jun 24; Vol. 384 (25), pp. 2382-2393.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Mutation*
Acetonitriles/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Colorectal Neoplasms/*drug therapy
Drug Resistance, Neoplasm/*genetics
Lung Neoplasms/*drug therapy
Piperazines/*therapeutic use
Proto-Oncogene Proteins p21(ras)/*genetics
Pyrimidines/*therapeutic use
Appendiceal Neoplasms/drug therapy ; Appendiceal Neoplasms/genetics ; Carcinoma, Non-Small-Cell Lung/genetics ; Colorectal Neoplasms/genetics ; Humans ; Lung Neoplasms/genetics ; Protein Conformation ; Proto-Oncogene Proteins p21(ras)/antagonists & inhibitors ; Proto-Oncogene Proteins p21(ras)/ultrastructure ; Pyridines/therapeutic use
Czasopismo naukowe
Tytuł :
Ras Isoforms from Lab Benches to Lives-What Are We Missing and How Far Are We?
Autorzy :
Nair A; National Centre for Cell Science, Ganeshkhind, Pune 411007, India.
Kubatzky KF; Department of Infectious Diseases, Medical Microbiology and Hygiene, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Saha B; National Centre for Cell Science, Ganeshkhind, Pune 411007, India.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Jun 17; Vol. 22 (12). Date of Electronic Publication: 2021 Jun 17.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Proto-Oncogene Proteins p21(ras)/*genetics
Biomarkers ; Biomarkers, Tumor ; Gene Expression Regulation ; Humans ; Mutation ; Protein Isoforms ; Proto-Oncogene Proteins p21(ras)/chemistry ; Proto-Oncogene Proteins p21(ras)/metabolism ; Research ; Signal Transduction ; Structure-Activity Relationship ; Translational Medical Research ; ras Proteins/metabolism
Czasopismo naukowe
Tytuł :
Targeting KRAS4A splicing through the RBM39/DCAF15 pathway inhibits cancer stem cells.
Autorzy :
Chen WC; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
To MD; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Westcott PMK; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.; MIT Koch Institute for Integrative Cancer Research, Cambridge, MA, USA.
Delrosario R; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Kim IJ; Guardant Health, Redwood City, California, USA.
Philips M; NYU Cancer Institute, NYU School of Medicine, New York, NY, USA.
Tran Q; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Bollam SR; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Goodarzi H; Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, USA.
Bayani N; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Mirzoeva O; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Balmain A; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. .; Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, USA. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2021 Jul 13; Vol. 12 (1), pp. 4288. Date of Electronic Publication: 2021 Jul 13.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Intracellular Signaling Peptides and Proteins/*metabolism
Neoplastic Stem Cells/*metabolism
Proto-Oncogene Proteins p21(ras)/*metabolism
RNA-Binding Proteins/*metabolism
A549 Cells ; Animals ; Blotting, Western ; Cell Proliferation ; Flow Cytometry ; Heterografts ; Humans ; Intracellular Signaling Peptides and Proteins/genetics ; Mice ; Mice, Knockout ; Polymerase Chain Reaction ; Proto-Oncogene Proteins p21(ras)/genetics ; RNA-Binding Proteins/genetics
Czasopismo naukowe
Tytuł :
Highly metastatic claudin-low mammary cancers can originate from luminal epithelial cells.
Autorzy :
Rädler PD; Department of Oncology, Wayne State University School of Medicine and Tumor Biology Program, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA.; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA.
Wehde BL; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA.
Triplett AA; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA.
Shrestha H; Department of Oncology, Wayne State University School of Medicine and Tumor Biology Program, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA.
Shepherd JH; Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Pfefferle AD; Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Rui H; Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA.
Cardiff RD; Center of Comparative Medicine, University of California, Davis, CA, USA.
Perou CM; Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Wagner KU; Department of Oncology, Wayne State University School of Medicine and Tumor Biology Program, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2021 Jun 18; Vol. 12 (1), pp. 3742. Date of Electronic Publication: 2021 Jun 18.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Claudins/*metabolism
Mammary Glands, Animal/*pathology
Mammary Neoplasms, Animal/*genetics
Mesenchymal Stem Cells/*metabolism
Proto-Oncogene Proteins p21(ras)/*metabolism
Animals ; Cell Differentiation ; Cell Line, Tumor ; Epithelial Cells/pathology ; Epithelial-Mesenchymal Transition/genetics ; Female ; Gene Expression Regulation, Neoplastic/genetics ; Mammary Neoplasms, Animal/pathology ; Mice ; Mice, Knockout ; Proto-Oncogene Proteins p21(ras)/genetics ; Triple Negative Breast Neoplasms/genetics
Czasopismo naukowe
Tytuł :
Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project.
Autorzy :
Finn SP; Cancer Molecular Diagnostics Laboratory, Institute of Molecular Medicine, St. James Hospital, Dublin, Ireland. Electronic address: .
Addeo A; Department of Oncology, University Hospital Geneva, Geneva, Switzerland.
Dafni U; ETOP Statistics Center, Frontier Science Foundation-Hellas, Athens, Greece; Department of Nursing, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece.
Thunnissen E; Department of Pathology, Free University Medical Center, Amsterdam, the Netherlands.
Bubendorf L; Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
Madsen LB; Department of Pathology, Aarhus University Hospital, Aarhus, Denmark.
Biernat W; Department of Pathology, Medical University of Gdansk, Gdansk, Poland.
Verbeken E; Department of Pathology, University Hospital KU Leuven, Leuven, Belgium.
Hernandez-Losa J; Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain.
Marchetti A; Department of Pathology, Ospedale Clinicizzato Chieti, Chieti, Italy.
Cheney R; Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Warth A; Department of Pathology, Universitätsklinikum Heidelberg, Heidelberg, Germany.
Speel EM; Department of Pathology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands.
Quinn AM; Department of Histopathology, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, United Kingdom.
Monkhorst K; Division of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Jantus-Lewintre E; Department of Biotechnology, Universitat Politècnica de València, Valencia, Spain; Mixed Unit TRIAL (General University Hospital Valencia Research Foundation and Píncipe Felipe Research Center), Valencia, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Valencia, Spain.
Tischler V; Division of Pathology, University Hospital Zurich, Zurich, Switzerland.
Marti N; European Thoracic Oncology Platform, Bern, Switzerland.
Dimopoulou G; ETOP Statistics Center, Frontier Science Foundation-Hellas, Athens, Greece.
Molina-Vila MA; Laboratory of Oncology, Pangaea Oncology S.A, Barcelona, Spain.
Kammler R; European Thoracic Oncology Platform, Bern, Switzerland.
Kerr KM; Department of Pathology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom.
Peters S; Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Stahel RA; European Thoracic Oncology Platform, Bern, Switzerland.
Pokaż więcej
Corporate Authors :
European Thoracic Oncology Platform Lungscape Investigators
Źródło :
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2021 Jun; Vol. 16 (6), pp. 990-1002. Date of Electronic Publication: 2021 Feb 26.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Lung Neoplasms*/genetics
Proto-Oncogene Proteins p21(ras)*/genetics
Humans ; Mutation ; Neoplasm Recurrence, Local ; Piperazines ; Prognosis ; Pyridines ; Pyrimidines
Czasopismo naukowe
Tytuł :
One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS.
Autorzy :
Ramharter J; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
Kessler D; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
Ettmayer P; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
Hofmann MH; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
Gerstberger T; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
Gmachl M; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
Wunberg T; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
Kofink C; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
Sanderson M; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
Arnhof H; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
Bader G; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
Rumpel K; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
Zöphel A; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
Schnitzer R; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
Böttcher J; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
O'Connell JC; Forma Therapeutics, 500 Arsenal Street, Suite 100, Watertown, Massachusetts 02472, United States.
Mendes RL; Forma Therapeutics, 500 Arsenal Street, Suite 100, Watertown, Massachusetts 02472, United States.
Richard D; Forma Therapeutics, 500 Arsenal Street, Suite 100, Watertown, Massachusetts 02472, United States.
Pototschnig N; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
Weiner I; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
Hela W; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
Hauer K; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
Haering D; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
Lamarre L; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
Wolkerstorfer B; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
Salamon C; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
Werni P; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
Munico-Martinez S; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
Meyer R; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
Kennedy MD; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
Kraut N; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
McConnell DB; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
Pokaż więcej
Źródło :
Journal of medicinal chemistry [J Med Chem] 2021 May 27; Vol. 64 (10), pp. 6569-6580. Date of Electronic Publication: 2021 Mar 15.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Proto-Oncogene Proteins p21(ras)/*metabolism
SOS1 Protein/*metabolism
Afatinib/chemistry ; Afatinib/metabolism ; Afatinib/therapeutic use ; Allosteric Regulation/drug effects ; Binding Sites ; Catalytic Domain ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/pathology ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/metabolism ; Humans ; Molecular Dynamics Simulation ; Mutagenesis, Site-Directed ; Protein Interaction Maps/drug effects ; Proto-Oncogene Proteins p21(ras)/antagonists & inhibitors ; Proto-Oncogene Proteins p21(ras)/genetics ; Quinazolines/chemistry ; Quinazolines/metabolism ; Quinazolines/pharmacology ; Quinazolines/therapeutic use ; SOS1 Protein/agonists ; SOS1 Protein/antagonists & inhibitors ; SOS1 Protein/genetics
Czasopismo naukowe
Tytuł :
Selective and noncovalent targeting of RAS mutants for inhibition and degradation.
Autorzy :
Teng KW; Perlmutter Cancer Center, New York University Langone Health, New York, NY, USA.
Tsai ST; Perlmutter Cancer Center, New York University Langone Health, New York, NY, USA.
Hattori T; Perlmutter Cancer Center, New York University Langone Health, New York, NY, USA.; Department of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY, USA.
Fedele C; Perlmutter Cancer Center, New York University Langone Health, New York, NY, USA.
Koide A; Perlmutter Cancer Center, New York University Langone Health, New York, NY, USA.; Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA.
Yang C; Department of Chemistry, New York University, New York, NY, USA.
Hou X; Department of Chemistry, New York University, New York, NY, USA.
Zhang Y; Department of Chemistry, New York University, New York, NY, USA.
Neel BG; Perlmutter Cancer Center, New York University Langone Health, New York, NY, USA.; Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA.
O'Bryan JP; Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, SC, USA.; Ralph H. Johnson VA Medical Center, Charleston, SC, USA.
Koide S; Perlmutter Cancer Center, New York University Langone Health, New York, NY, USA. .; Department of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY, USA. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2021 May 11; Vol. 12 (1), pp. 2656. Date of Electronic Publication: 2021 May 11.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Mutation*
Antibodies, Monoclonal/*pharmacology
Mutant Proteins/*antagonists & inhibitors
Neoplasms/*drug therapy
Proto-Oncogene Proteins p21(ras)/*genetics
Xenograft Model Antitumor Assays/*methods
Animals ; Antibodies, Monoclonal/chemistry ; Antibodies, Monoclonal/metabolism ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Female ; HEK293 Cells ; Humans ; Mice, Nude ; Mutant Proteins/metabolism ; Neoplasms/genetics ; Neoplasms/metabolism ; Protein Binding ; Proteolysis/drug effects ; Proto-Oncogene Proteins p21(ras)/immunology ; Proto-Oncogene Proteins p21(ras)/metabolism
Czasopismo naukowe
Tytuł :
Molecular Docking and Biophysical Studies for Antiproliferative Assessment of Synthetic Pyrazolo-Pyrimidinones Tethered with Hydrazide-Hydrazones.
Autorzy :
Horchani M; Laboratory of Heterocyclic Chemistry, Natural Products and Reactivity, Medicinal Chemistry and Natural Products (LR11ES39), Faculty of Sciences of Monastir, University of Monastir, 5000 Monastir, Tunisia.
Della Sala G; Department of Marine Biotechnology, Stazione Zoologica Anton Dohrn, Villa Comunale, 80125 Naples, Italy.; Laboratory of Pre-Clinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata, 85028 Rionero in Vulture, Italy.
Caso A; The Blue Chemistry Lab, Department of Pharmacy, University of Naples Federico II, Via D. Montesano 49, 80131 Naples, Italy.
D'Aria F; Department of Pharmacy, University of Naples Federico II, Via D. Montesano 49, 80131 Naples, Italy.
Esposito G; The Blue Chemistry Lab, Department of Pharmacy, University of Naples Federico II, Via D. Montesano 49, 80131 Naples, Italy.
Laurenzana I; Laboratory of Pre-Clinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata, 85028 Rionero in Vulture, Italy.
Giancola C; Department of Pharmacy, University of Naples Federico II, Via D. Montesano 49, 80131 Naples, Italy.
Costantino V; The Blue Chemistry Lab, Department of Pharmacy, University of Naples Federico II, Via D. Montesano 49, 80131 Naples, Italy.
Jannet HB; Laboratory of Heterocyclic Chemistry, Natural Products and Reactivity, Medicinal Chemistry and Natural Products (LR11ES39), Faculty of Sciences of Monastir, University of Monastir, 5000 Monastir, Tunisia.
Romdhane A; Laboratory of Heterocyclic Chemistry, Natural Products and Reactivity, Medicinal Chemistry and Natural Products (LR11ES39), Faculty of Sciences of Monastir, University of Monastir, 5000 Monastir, Tunisia.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Mar 08; Vol. 22 (5). Date of Electronic Publication: 2021 Mar 08.
Typ publikacji :
Journal Article
MeSH Terms :
Breast Neoplasms*/drug therapy
Breast Neoplasms*/metabolism
Breast Neoplasms*/pathology
G-Quadruplexes*
Molecular Docking Simulation*
Proto-Oncogene Proteins p21(ras)*/antagonists & inhibitors
Proto-Oncogene Proteins p21(ras)*/chemistry
Proto-Oncogene Proteins p21(ras)*/metabolism
Pyrimidinones*/chemical synthesis
Pyrimidinones*/chemistry
Pyrimidinones*/pharmacology
Apoptosis/*drug effects
Cell Proliferation/*drug effects
Antineoplastic Agents ; Drug Screening Assays, Antitumor ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/chemistry ; ErbB Receptors/metabolism ; Female ; Humans ; MCF-7 Cells
Czasopismo naukowe
Tytuł :
KRAS drives immune evasion in a genetic model of pancreatic cancer.
Autorzy :
Ischenko I; Department of Molecular Genetics and Microbiology, Stony Brook University, Stony Brook, NY, USA.
D'Amico S; Department of Molecular Genetics and Microbiology, Stony Brook University, Stony Brook, NY, USA.
Rao M; Department of Pathology, Stony Brook University, Stony Brook, NY, USA.
Li J; Department of Pathology, Stony Brook University, Stony Brook, NY, USA.
Hayman MJ; Department of Molecular Genetics and Microbiology, Stony Brook University, Stony Brook, NY, USA.
Powers S; Department of Pathology, Stony Brook University, Stony Brook, NY, USA.
Petrenko O; Department of Molecular Genetics and Microbiology, Stony Brook University, Stony Brook, NY, USA. .
Reich NC; Department of Molecular Genetics and Microbiology, Stony Brook University, Stony Brook, NY, USA. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2021 Mar 05; Vol. 12 (1), pp. 1482. Date of Electronic Publication: 2021 Mar 05.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Models, Genetic*
Immune Evasion/*physiology
Pancreatic Neoplasms/*immunology
Proto-Oncogene Proteins p21(ras)/*genetics
Proto-Oncogene Proteins p21(ras)/*metabolism
Animals ; Carcinoma, Pancreatic Ductal/genetics ; Carcinoma, Pancreatic Ductal/pathology ; Cytokines/metabolism ; Disease Models, Animal ; Female ; Gene Editing ; Gene Expression Profiling ; Humans ; Male ; Mice ; Mice, Inbred C57BL ; Mice, Knockout ; Mice, Nude ; Pancreatic Ducts/pathology ; Pancreatic Neoplasms/genetics ; Pancreatic Neoplasms/pathology ; Proto-Oncogene Proteins p21(ras)/immunology ; Transcriptome
SCR Disease Name :
Pancreatic Carcinoma
Czasopismo naukowe
Tytuł :
Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer.
Autorzy :
Chao YC; Department of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.; Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.
Lee KY; Shuang Ho Hospital, Taipei Medical University, New Taipei City 235, Taiwan.; Division of Pulmonary Medicine, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.; Graduate Institute of Clinical Sciences, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.
Wu SM; Shuang Ho Hospital, Taipei Medical University, New Taipei City 235, Taiwan.; Division of Pulmonary Medicine, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.
Kuo DY; Division of Radiation Oncology, Far Eastern Memorial Hospital, New Taipei City 220, Taiwan.
Shueng PW; Division of Radiation Oncology, Far Eastern Memorial Hospital, New Taipei City 220, Taiwan.; Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.
Lin CW; Department of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.; Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.; Cell Physiology and Molecular Image Research Center, Wan Fang Hospital, Taipei Medical University, Taipei 110, Taiwan.; Drug Development and Value Creation Research Center, Kaohsiung Medical University, Kaohsiung 817, Taiwan.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 May 26; Vol. 22 (11). Date of Electronic Publication: 2021 May 26.
Typ publikacji :
Journal Article
MeSH Terms :
Mutation*
B7-H1 Antigen/*immunology
Carcinoma, Non-Small-Cell Lung/*immunology
Down-Regulation/*immunology
Gene Expression Regulation, Neoplastic/*immunology
Lung Neoplasms/*immunology
Proto-Oncogene Proteins p21(ras)/*immunology
A549 Cells ; Animals ; B7-H1 Antigen/genetics ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Mice ; Proto-Oncogene Proteins p21(ras)/genetics
Czasopismo naukowe
Tytuł :
Monoubiquitination of KRAS at Lysine104 and Lysine147 Modulates Its Dynamics and Interaction with Partner Proteins.
Autorzy :
Nair VV; Department of Integrative Biology and Pharmacology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas 77030, United States.; MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences, University of Texas Health Science Center at Houston, Houston, Texas 77030, United States.
Yin G; Department of Biochemistry and Biophysics, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.; The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518107, Guangdong, China.
Zhang J; Department of Biochemistry and Biophysics, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Hancock JF; Department of Integrative Biology and Pharmacology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas 77030, United States.; MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences, University of Texas Health Science Center at Houston, Houston, Texas 77030, United States.
Campbell SL; Department of Biochemistry and Biophysics, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27514, United States.
Gorfe AA; Department of Integrative Biology and Pharmacology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas 77030, United States.; MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences, University of Texas Health Science Center at Houston, Houston, Texas 77030, United States.
Pokaż więcej
Źródło :
The journal of physical chemistry. B [J Phys Chem B] 2021 May 13; Vol. 125 (18), pp. 4681-4691. Date of Electronic Publication: 2021 Apr 30.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Molecular Dynamics Simulation*
Proto-Oncogene Proteins p21(ras)*/genetics
Protein Processing, Post-Translational ; Ubiquitin ; Ubiquitination
Czasopismo naukowe
Tytuł :
KRAS, A Prime Mediator in Pancreatic Lipid Synthesis through Extra Mitochondrial Glutamine and Citrate Metabolism.
Autorzy :
Muyinda IJ; Department of Translational Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang-si 10408, Korea.; Uganda Cancer Institute, Mulago-Kampala 3935, Uganda.
Park JG; Department of Translational Science, Research Institute, National Cancer Center, Goyang-si 10408, Korea.
Jang EJ; Department of Translational Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang-si 10408, Korea.
Yoo BC; Department of Translational Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang-si 10408, Korea.; Department of Translational Science, Research Institute, National Cancer Center, Goyang-si 10408, Korea.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 May 11; Vol. 22 (10). Date of Electronic Publication: 2021 May 11.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Citrates/*metabolism
Glutamine/*metabolism
Lipids/*analysis
Mitochondria/*metabolism
Pancreas/*metabolism
Pancreatic Neoplasms/*metabolism
Proto-Oncogene Proteins p21(ras)/*metabolism
Humans ; Pancreas/cytology ; Pancreatic Neoplasms/pathology ; Proto-Oncogene Proteins p21(ras)/genetics
Czasopismo naukowe
Tytuł :
Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers.
Autorzy :
Peng DH; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Perlmutter Cancer Center, NYU Langone Health, 550 First Avenue, Smilow Building 10th Floor, Suite 1010, New York, NY, USA.
Rodriguez BL; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Diao L; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Gaudreau PO; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Thoracic & Upper GI Cancer Research Laboratories, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Padhye A; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; The University of Texas MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences, Houston, TX, USA.
Konen JM; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ochieng JK; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Class CA; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fradette JJ; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Gibson L; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Chen L; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wang J; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Byers LA; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Gibbons DL; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. .; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2021 May 10; Vol. 12 (1), pp. 2606. Date of Electronic Publication: 2021 May 10.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Antineoplastic Agents, Immunological/*pharmacology
B7-H1 Antigen/*metabolism
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Mitogen-Activated Protein Kinase Kinases/*antagonists & inhibitors
Proto-Oncogene Proteins p21(ras)/*genetics
Th17 Cells/*metabolism
Tumor Suppressor Protein p53/*genetics
Animals ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; B7-H1 Antigen/immunology ; CD4-Positive T-Lymphocytes/drug effects ; CD4-Positive T-Lymphocytes/immunology ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/pathology ; Cell Line, Tumor ; Drug Resistance, Neoplasm/immunology ; Drug Synergism ; Female ; Humans ; Immune Checkpoint Inhibitors/immunology ; Immunohistochemistry ; Lung Neoplasms/genetics ; Lung Neoplasms/metabolism ; Lung Neoplasms/pathology ; MAP Kinase Signaling System/drug effects ; MAP Kinase Signaling System/genetics ; Male ; Mice ; Mice, Knockout ; Mitogen-Activated Protein Kinase Kinases/metabolism ; Neoplasm Invasiveness/genetics ; Neoplasm Invasiveness/immunology ; Neoplasm Metastasis ; Protein Kinase Inhibitors/therapeutic use ; Proto-Oncogene Proteins p21(ras)/metabolism ; Th17 Cells/immunology ; Tumor Suppressor Protein p53/metabolism
Czasopismo naukowe
Tytuł :
Scaffold repurposing of fendiline: Identification of potent KRAS plasma membrane localization inhibitors.
Autorzy :
Wang P; Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
van der Hoeven D; Department of Diagnostic and Biomedical Sciences, School of Dentistry, The University of Texas Health Science Center at Houston, Houston, TX, 77054, USA.
Ye N; Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
Chen H; Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
Liu Z; Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
Ma X; Department of Integrative Biology and Pharmacology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Montufar-Solis D; Department of Integrative Biology and Pharmacology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Rehl KM; Department of Biochemistry and Molecular Biology, Boonshoft School of Medicine, Wright State University, Dayton, OH, 45435, USA.
Cho KJ; Department of Biochemistry and Molecular Biology, Boonshoft School of Medicine, Wright State University, Dayton, OH, 45435, USA.
Thapa S; Department of Diagnostic and Biomedical Sciences, School of Dentistry, The University of Texas Health Science Center at Houston, Houston, TX, 77054, USA.
Chen W; Department of Integrative Biology and Pharmacology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
van der Hoeven R; Department of Diagnostic and Biomedical Sciences, School of Dentistry, The University of Texas Health Science Center at Houston, Houston, TX, 77054, USA.
Frost JA; Department of Integrative Biology and Pharmacology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Hancock JF; Department of Integrative Biology and Pharmacology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA. Electronic address: .
Zhou J; Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, 77555, USA. Electronic address: .
Pokaż więcej
Źródło :
European journal of medicinal chemistry [Eur J Med Chem] 2021 May 05; Vol. 217, pp. 113381. Date of Electronic Publication: 2021 Mar 15.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*pharmacology
Cell Membrane/*drug effects
Enzyme Inhibitors/*pharmacology
Fendiline/*pharmacology
Proto-Oncogene Proteins p21(ras)/*antagonists & inhibitors
Animals ; Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Cell Membrane/metabolism ; Cell Proliferation/drug effects ; Cells, Cultured ; Dogs ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Enzyme Inhibitors/chemical synthesis ; Enzyme Inhibitors/chemistry ; Female ; Fendiline/analogs & derivatives ; Fendiline/chemistry ; Humans ; Mice ; Mice, Nude ; Molecular Structure ; Neoplasms, Experimental/drug therapy ; Neoplasms, Experimental/metabolism ; Neoplasms, Experimental/pathology ; Proto-Oncogene Proteins p21(ras)/metabolism ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł :
Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy.
Autorzy :
Noordhof AL; Department of Respiratory Medicine, Medical Center Leeuwarden, Henri Dunantweg 2, 8934 AD, Leeuwarden, the Netherlands.
Damhuis RAM; Department of Research, Comprehensive Cancer Organization, Plesmanlaan 121, 1066 CX, Utrecht, the Netherlands.
Hendriks LEL; Department of Respiratory Medicine, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, P. Debyelaan 25, 6229 HX, Maastricht, the Netherlands.
de Langen AJ; Department of Thoracic Oncology, Netherlands Cancer Institute, NA 1007 MB, Amsterdam, the Netherlands.
Timens W; Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands.
Venmans BJW; Department of Respiratory Medicine, Medical Center Leeuwarden, Henri Dunantweg 2, 8934 AD, Leeuwarden, the Netherlands.
van Geffen WH; Department of Respiratory Medicine, Medical Center Leeuwarden, Henri Dunantweg 2, 8934 AD, Leeuwarden, the Netherlands. Electronic address: .
Pokaż więcej
Źródło :
Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2021 May; Vol. 155, pp. 163-169. Date of Electronic Publication: 2021 Apr 05.
Typ publikacji :
Journal Article
MeSH Terms :
Adenocarcinoma*/drug therapy
Adenocarcinoma*/genetics
Carcinoma, Non-Small-Cell Lung*
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Proto-Oncogene Proteins p21(ras)*/genetics
Antibodies, Monoclonal, Humanized ; B7-H1 Antigen/genetics ; B7-H1 Antigen/metabolism ; Humans ; Lung/metabolism ; Mutation ; Netherlands ; Prognosis ; Protein-Tyrosine Kinases/genetics ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Construction of a reference material panel for detecting KRAS / NRAS / EGFR / BRAF / MET mutations in plasma ctDNA.
Autorzy :
Xu J; Department of Neurosurgery, China-Japan Friendship Hospital, Beijing, China.
Qu S; Division of Diagnostic for Non-infectious Disease, National Institutes for Food and Drug Control, Beijing, China.
Sun N; Division of Diagnostic for Non-infectious Disease, National Institutes for Food and Drug Control, Beijing, China.
Zhang W; Division of Diagnostic for Non-infectious Disease, National Institutes for Food and Drug Control, Beijing, China.
Zhang J; Department of Invitro Diagnostic Reagents Testing, Henan Medical Equipment Inspection Institute, Zhengzhou, China.
Song Q; R&D Center, Amoy Diagnostics Co., Ltd, Xiamen, China.
Lin M; Oncology Business Unit, BGI Geonmics Co., Ltd, Shenzhen, China.
Gao W; R&D Center, Geneplus-Beijing Institute, Beijing, China.
Zheng Q; R&D Center, Genetron Health (Beijing) Co, Beijing, China.
Han M; R&D Center, Berry Genomics Co., Ltd, Beijing, China.
Na C; R&D Center, Nanjing Geneseeq Technology Inc, Nanjing, China.
Xu R; R&D Center, Shanghai Yuanqi Bio-Pharmaceutical Co. Ltd, Shanghai, China.
Chang X; Department of Pathology, Peking Union Medical College Hospital, Beijing, China .
Yang X; School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China .
Huang J; Division of Diagnostic for Non-infectious Disease, National Institutes for Food and Drug Control, Beijing, China .
Pokaż więcej
Źródło :
Journal of clinical pathology [J Clin Pathol] 2021 May; Vol. 74 (5), pp. 314-320. Date of Electronic Publication: 2020 Aug 17.
Typ publikacji :
Journal Article; Multicenter Study
MeSH Terms :
Mutation*
Biomarkers, Tumor/*genetics
Carcinoma, Non-Small-Cell Lung/*genetics
Circulating Tumor DNA/*genetics
DNA Mutational Analysis/*standards
GTP Phosphohydrolases/*genetics
High-Throughput Nucleotide Sequencing/*standards
Lung Neoplasms/*genetics
Membrane Proteins/*genetics
Proto-Oncogene Proteins B-raf/*genetics
Proto-Oncogene Proteins c-met/*genetics
Proto-Oncogene Proteins p21(ras)/*genetics
Adult ; Beijing ; Biomarkers, Tumor/blood ; Carcinoma, Non-Small-Cell Lung/blood ; Carcinoma, Non-Small-Cell Lung/diagnosis ; Cell Line, Tumor ; Circulating Tumor DNA/blood ; ErbB Receptors/blood ; ErbB Receptors/genetics ; Female ; GTP Phosphohydrolases/blood ; Humans ; Liquid Biopsy/standards ; Lung Neoplasms/blood ; Lung Neoplasms/diagnosis ; Male ; Membrane Proteins/blood ; Middle Aged ; Predictive Value of Tests ; Proto-Oncogene Proteins B-raf/blood ; Proto-Oncogene Proteins c-met/blood ; Proto-Oncogene Proteins p21(ras)/blood ; Reference Standards ; Young Adult
Czasopismo naukowe
Tytuł :
A KRAS-responsive long non-coding RNA controls microRNA processing.
Autorzy :
Shi L; Transcriptional Networks in Lung Cancer Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK.; Cancer Research UK Lung Cancer Centre of Excellence, at Manchester and University College London, London, UK.
Magee P; Transcriptional Networks in Lung Cancer Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK.; Cancer Research UK Lung Cancer Centre of Excellence, at Manchester and University College London, London, UK.
Fassan M; Department of Medicine, Surgical Pathology & Cytopathology Unit, University of Padua, Padua, Italy.
Sahoo S; Computational Biology Support, Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK.
Leong HS; Computational Biology Support, Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK.
Lee D; Computational Biology Support, Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK.
Sellers R; Computational Biology Support, Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK.
Brullé-Soumaré L; Xentech, 4 rue Pierre Fontaine, Evry, France.
Cairo S; Xentech, 4 rue Pierre Fontaine, Evry, France.
Monteverde T; Transcriptional Networks in Lung Cancer Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK.; Cancer Research UK Lung Cancer Centre of Excellence, at Manchester and University College London, London, UK.
Volinia S; Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.
Smith DD; Biological Mass Spectrometry Facility, Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK.
Di Leva G; School of Pharmacy and Bioengineering, Keele University, Stock-on-Trent, UK.
Galuppini F; Department of Medicine, Surgical Pathology & Cytopathology Unit, University of Padua, Padua, Italy.
Paliouras AR; Transcriptional Networks in Lung Cancer Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK.; Cancer Research UK Lung Cancer Centre of Excellence, at Manchester and University College London, London, UK.
Zeng K; Imaging & Cytometry Facility, Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK.
O'Keefe R; Division of Evolution & Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Garofalo M; Transcriptional Networks in Lung Cancer Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK. .; Cancer Research UK Lung Cancer Centre of Excellence, at Manchester and University College London, London, UK. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2021 Apr 01; Vol. 12 (1), pp. 2038. Date of Electronic Publication: 2021 Apr 01.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Gene Expression Regulation, Neoplastic*
Carcinoma, Non-Small-Cell Lung/*genetics
Lung Neoplasms/*genetics
MicroRNAs/*genetics
Proto-Oncogene Proteins p21(ras)/*genetics
RNA, Long Noncoding/*genetics
A549 Cells ; Animals ; Carcinoma, Non-Small-Cell Lung/metabolism ; Carcinoma, Non-Small-Cell Lung/therapy ; Cell Line, Tumor ; Female ; Gene Expression Profiling/methods ; Gene Ontology ; Humans ; Kaplan-Meier Estimate ; Lung Neoplasms/metabolism ; Lung Neoplasms/therapy ; Mice, Inbred NOD ; Mice, Knockout ; Mice, SCID ; Proto-Oncogene Proteins p21(ras)/metabolism ; Xenograft Model Antitumor Assays/methods
Czasopismo naukowe
Tytuł :
Synergistic effects of piperlongumine and gemcitabine against KRAS mutant lung cancer.
Autorzy :
Ye W; Department of Respiratory Diseases, Zhejiang Hospital, Hangzhou, Zhejiang Province, People's Republic of China.
Huang Q; Department of Respiratory Diseases, Zhejiang Hospital, Hangzhou, Zhejiang Province, People's Republic of China.
Tang T; Department of Respiratory Diseases, Zhejiang Hospital, Hangzhou, Zhejiang Province, People's Republic of China.
Qin G; Department of Respiratory Diseases, Zhejiang Hospital, Hangzhou, Zhejiang Province, People's Republic of China.
Pokaż więcej
Źródło :
Tumori [Tumori] 2021 Apr; Vol. 107 (2), pp. 119-124. Date of Electronic Publication: 2020 Jun 09.
Typ publikacji :
Journal Article
MeSH Terms :
Mutation*
Apoptosis/*drug effects
Deoxycytidine/*analogs & derivatives
Dioxolanes/*pharmacology
Lung Neoplasms/*genetics
Proto-Oncogene Proteins p21(ras)/*genetics
A549 Cells ; Antimetabolites, Antineoplastic/pharmacology ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Deoxycytidine/pharmacology ; Drug Synergism ; Humans ; Lung Neoplasms/metabolism ; Lung Neoplasms/pathology ; Microtubule-Associated Proteins/metabolism ; Proto-Oncogene Proteins p21(ras)/metabolism ; Reactive Oxygen Species/metabolism
Czasopismo naukowe
Tytuł :
RGD4C peptide mediates anti-p21Ras scFv entry into tumor cells and produces an inhibitory effect on the human colon cancer cell line SW480.
Autorzy :
Huang CC; School of Medicine, Kunming University of Science and Technology, 727 South Jing Ming Road, Chenggong County, Kunming, 650500, Yunnan Province, China.; Department of Pathology, 920th Hospital of Joint Logistics Support Force of PLA, 212Daguan Rd, Xishan District, Kunming, 650032, Yunnan Province, China.
Liu FR; School of Medicine, Kunming University of Science and Technology, 727 South Jing Ming Road, Chenggong County, Kunming, 650500, Yunnan Province, China.
Feng Q; Department of Pathology, 920th Hospital of Joint Logistics Support Force of PLA, 212Daguan Rd, Xishan District, Kunming, 650032, Yunnan Province, China.
Pan XY; Department of Pathology, 920th Hospital of Joint Logistics Support Force of PLA, 212Daguan Rd, Xishan District, Kunming, 650032, Yunnan Province, China.
Song SL; Department of Pathology, 920th Hospital of Joint Logistics Support Force of PLA, 212Daguan Rd, Xishan District, Kunming, 650032, Yunnan Province, China.
Yang JL; School of Medicine, Kunming University of Science and Technology, 727 South Jing Ming Road, Chenggong County, Kunming, 650500, Yunnan Province, China. .; Department of Pathology, 920th Hospital of Joint Logistics Support Force of PLA, 212Daguan Rd, Xishan District, Kunming, 650032, Yunnan Province, China. .
Pokaż więcej
Źródło :
BMC cancer [BMC Cancer] 2021 Mar 25; Vol. 21 (1), pp. 321. Date of Electronic Publication: 2021 Mar 25.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents, Immunological/*pharmacology
Colonic Neoplasms/*drug therapy
Proto-Oncogene Proteins p21(ras)/*antagonists & inhibitors
Recombinant Fusion Proteins/*pharmacology
Antineoplastic Agents, Immunological/isolation & purification ; Antineoplastic Agents, Immunological/therapeutic use ; Apoptosis/drug effects ; Cell Line, Tumor ; Cell Membrane/metabolism ; Cell Membrane Permeability/drug effects ; Cell Movement/drug effects ; Colonic Neoplasms/genetics ; Colonic Neoplasms/pathology ; Humans ; Immunoconjugates/genetics ; Immunoconjugates/isolation & purification ; Immunoconjugates/pharmacology ; Immunoconjugates/therapeutic use ; Proto-Oncogene Proteins p21(ras)/genetics ; Recombinant Fusion Proteins/genetics ; Recombinant Fusion Proteins/isolation & purification ; Recombinant Fusion Proteins/therapeutic use ; Single-Chain Antibodies/genetics ; Single-Chain Antibodies/isolation & purification ; Single-Chain Antibodies/pharmacology ; Single-Chain Antibodies/therapeutic use
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies